Cerus Corporation (CERS)

NASDAQ
6.190
+0.110(+1.81%)
After Hours
6.190
0.000(0.00%)
- Real-time Data
  • Volume:
    716,689
  • Bid/Ask:
    6.190/6.250
  • Day's Range:
    6.050 - 6.240

CERS Overview

Prev. Close
6.08
Day's Range
6.05-6.24
Revenue
130.11M
Open
6.15
52 wk Range
4.67-8.87
EPS
-0.36
Volume
716,689
Market Cap
1.06B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,451,144
P/E Ratio
-
Beta
1.22
1-Year Change
-3.43%
Shares Outstanding
171,626,791
Next Earnings Date
Nov 04, 2021
What is your sentiment on Cerus Corporation?
or
Market is currently closed. Voting is open during market hours.

Cerus Corporation News

Cerus Corporation Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellBuyBuyStrong Buy
Technical IndicatorsSellNeutralStrong BuyStrong SellNeutral
SummaryNeutralNeutralStrong BuyNeutralBuy

Cerus Corporation Company Profile

Cerus Corporation Company Profile

Employees
270

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Read More
  • Why the plunge yesterday on supposed good news? No mention of that anywhere.
    1
    • https://www.statnews.com/2020/08/23/fda-under-pressure-from-trump-expected-to-authorize-blood-plasma-as-covid-19-treatment/
      2
      • What's triggering the sudden rise?
        1
        • Think its the coronavirus scare, maybe testing
          1
        • Upcoming earnings on Feb 20
          2
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.